de Jong-van den Berg LT - Search Results

1

Teratogenic mechanisms of medical drugs.

van Gelder MM, van Rooij IA, Miller RK, Zielhuis GA, de Jong-van den Berg LT, Roeleveld N. van Gelder MM, et al. Hum Reprod Update. 2010 Jul-Aug;16(4):378-94. doi: 10.1093/humupd/dmp052. Epub 2010 Jan 7. Hum Reprod Update. 2010. PMID: 20061329 Free article. Review.

2

Drugs associated with teratogenic mechanisms. Part I: dispensing rates among pregnant women in the Netherlands, 1998-2009.

van Gelder MM, Bos JH, Roeleveld N, de Jong-van den Berg LT. van Gelder MM, et al. Hum Reprod. 2014 Jan;29(1):161-7. doi: 10.1093/humrep/det369. Epub 2013 Oct 8. Hum Reprod. 2014. PMID: 24105826

3

Drugs associated with teratogenic mechanisms. Part II: a literature review of the evidence on human risks.

van Gelder MM, de Jong-van den Berg LT, Roeleveld N. van Gelder MM, et al. Hum Reprod. 2014 Jan;29(1):168-83. doi: 10.1093/humrep/det370. Epub 2013 Oct 9. Hum Reprod. 2014. PMID: 24108217 Review.

4

Teratogenic mechanisms associated with prenatal medication exposure.

van Gelder MM, van Rooij IA, de Jong-van den Berg LT, Roeleveld N. van Gelder MM, et al. Therapie. 2014 Jan-Feb;69(1):13-24. doi: 10.2515/therapie/2014003. Epub 2014 Apr 4. Therapie. 2014. PMID: 24698184 Review.

5

Pharmacogenetics of drug-induced birth defects: what is known so far?

Wilffert B, Altena J, Tijink L, van Gelder MM, de Jong-van den Berg LT. Wilffert B, et al. Pharmacogenomics. 2011 Apr;12(4):547-58. doi: 10.2217/pgs.10.201. Pharmacogenomics. 2011. PMID: 21521026 Review.

6

Periconceptional health and lifestyle factors of both parents affect the risk of live-born children with orofacial clefts.

Krapels IP, Zielhuis GA, Vroom F, de Jong-van den Berg LT, Kuijpers-Jagtman AM, van der Molen AB, Steegers-Theunissen RP; Eurocran Gene-Environment Interaction Group. Krapels IP, et al. Birth Defects Res A Clin Mol Teratol. 2006 Aug;76(8):613-20. doi: 10.1002/bdra.20285. Birth Defects Res A Clin Mol Teratol. 2006. PMID: 16955502

7

Economic evaluation of anti-epileptic drug therapies with specific focus on teratogenic outcomes.

Jentink J, Boersma C, de Jong-van den Berg LT, Postma MJ. Jentink J, et al. J Med Econ. 2012;15(5):862-8. doi: 10.3111/13696998.2012.684366. Epub 2012 May 3. J Med Econ. 2012. PMID: 22494266 Free article.

8

Actual Use of Medications Prescribed During Pregnancy: A Cross-Sectional Study Using Data from a Population-Based Congenital Anomaly Registry.

de Jonge L, de Walle HE, de Jong-van den Berg LT, van Langen IM, Bakker MK. de Jonge L, et al. Drug Saf. 2015 Aug;38(8):737-47. doi: 10.1007/s40264-015-0302-z. Drug Saf. 2015. PMID: 26041497 Free PMC article.

9

Handling of risk-bearing drugs during pregnancy. Do we choose less risky alternatives?

De Jong-Van den Berg LT, Van den Berg PB, Haaijer-Ruskamp FM, Dukes MN, Wesseling H. De Jong-Van den Berg LT, et al. Pharm Weekbl Sci. 1992 Apr 24;14(2):38-45. doi: 10.1007/BF01980480. Pharm Weekbl Sci. 1992. PMID: 1528709

10

EUROmediCAT signal detection: a systematic method for identifying potential teratogenic medication.

Luteijn JM, Morris JK, Garne E, Given J, de Jong-van den Berg L, Addor MC, Bakker M, Barisic I, Gatt M, Klungsoyr K, Latos-Bielenska A, Lelong N, Nelen V, Neville A, O'Mahony M, Pierini A, Tucker D, de Walle H, Wiesel A, Loane M, Dolk H. Luteijn JM, et al. Br J Clin Pharmacol. 2016 Oct;82(4):1110-22. doi: 10.1111/bcp.13056. Epub 2016 Aug 4. Br J Clin Pharmacol. 2016. PMID: 27353147 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

279 results

Search Page